According to a Boston Business Journal story, Cambridge, Massachusetts-based biotech Acceleron Pharma has plans to test its ACE-083 compound in facioscapulohumeral muscular dystrophy patients in a phase 2 clinical trial later… Read More »
Acceleron plans to launch Phase 2 FSHD trial this year
Update on Early-Onset FSH Muscular Dystrophy Study
Insights on symptoms, biology, and quality of life By Yi-Wen Chen, PhD and Jean Mah, MD While most people with FSHD develop muscle weakness during late teen years or adulthood,… Read More »
Biology 101 for understanding the CRISPR research
Peter Jones, PhD, and Charis Himeda, PhD, found themselves unexpectedly in the media spotlight last week after publication of their paper on the application of CRISPR technology in FSHD cells. In… Read More »
Washington Post features FSH muscular dystrophy story
Today’s Washington Post featured a report on work by a research team that was described in an FSH Society press release. The Post story, “How CRISPR could lead to a cure for… Read More »
Dogs destined to develop muscular dystrophy evade their genetic fate
Golden retrievers with the Duchenne mutation show that disease-modifying genes may provide routes to treat a genetic disorder; possible parallels to facioscapulohumeral muscular dystrophy. Research led by Louis M. Kunkel,… Read More »